Nan Fung Life Sciences
Dianna, joined Pivotal China in 2018 as a Partner. During the preceding 7 years, she worked at two well-established US dollar funds (Fidelity Asia Growth Partners and Foutainvest) as the core investment team members of their healthcare practice. Prior to that, Dianna was the Vice President at Boehringer Ingelheim China in charge of Corporate Strategy & Business Development and New Product Planning, where she led the strategic alliance of BI and Eli Lily and licensed in several products in different therapeutic areas. Dianna started her career at BCG and later became an Engagement Manager at McKinsey’s China and US offices specializing in healthcare sector.
This person is not in the org chart
This person is not in any offices
Nan Fung Life Sciences
Nan Fung Life Sciences, part of Nan Fung Group, is a global investment platform focusing on life sciences. Leveraging on Nan Fung Group’s strong capital base and long-term commitment to the area, the company is aimed to become the ideal partner for scientists, entrepreneurs, corporations, and investors in the life science space. Through direct investments via Pivotal bioVenture Partners funds (both in US and China) and fund investments covering full spectrum of the industry (including therapeutics, medical devices, and diagnostics) and across different development stages, Nan Fung Life Sciences has a significant presence in both US and Greater China.